Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer鈥擟DK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update
<乌鸦传媒視頻 class="mpt-content-deck">鈥� An ASCO Reading Room selection July 16, 2024This Reading Room is a collaboration between 乌鸦传媒視頻庐 and:
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the . The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients.
In 2020, ASCO published a guideline on the selection of optimal . This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.
Read an interview about the guideline update here and expert commentary about it here.
Read the full article
Optimal Adjuvant Chemo and Targeted Therapy for Early Breast Cancer鈥擟DK 4/6 Inhibitors: ASCO Guideline Rapid Recommendation Update
Primary Source
Journal of Clinical Oncology
Source Reference: